Mercator MedSystems

Focus: Mercator MedSystems specializes in catheter-guided infusion systems for cardiovascular and oncology applications, operating as a focused medical device company from San Leandro, CA.

Cardiovascular Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Mercator MedSystems

AI assessmentNot Hiring

No open roles listed right now. Follow Mercator MedSystems to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Balloon Angioplasty

Peripheral Arterial Disease

N/A

Clinical Trials (1)

NCT02469532DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes

N/A

Help build intelligence for Mercator MedSystems

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-unmet-need areas: 6 Phase 2 programs and 1 Phase 3 program targeting peripheral arterial disease, chronic limb ischemia, and thrombosis
Proprietary catheter-guided delivery platform creates defensible competitive moat in cardiovascular and oncology spaces
Early-to-mid stage development provides opportunity to shape clinical strategy and see molecules progress through pivotal trials

Watch Out For

Currently zero active job openings suggests minimal near-term hiring or potential financial constraints
Limited public visibility: no disclosed funding, revenue, employee count, or recent news makes financial runway and company health opaque
Heavy concentration in Phase 2 (6 of 7 active trials) means regulatory catalysts are 2-3+ years away with no near-term revenue inflection expected

Generated by Claude from Mercator MedSystems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Paclitaxel

Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT02066103Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients

N/A

Perivascular dexamethasone

Thrombosis, Deep Vein

Phase 2

Clinical Trials (1)

NCT04862468Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

Phase 2

Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL

Chronic Limb Ischemia

Phase 2

Clinical Trials (1)

NCT02479620Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization

Phase 2

Dexamethasone sodium phosphate injection, USP, 4 mg/mL

Chronic Limb Ischemia

Phase 2

Clinical Trials (1)

NCT02479555Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization

Phase 2

Temsirolimus

Peripheral Arterial Disease

Phase 2

Clinical Trials (1)

NCT03942601Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Phase 2

Temsirolimus

Chronic Limb Ischemia

Phase 2

Clinical Trials (1)

NCT02908035Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

Phase 2

Perivascular dexamethasone

Iliofemoral; Thrombosis

Phase 2

Clinical Trials (1)

NCT04858776Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

Phase 2

Temsirolimus

Peripheral Artery Disease

Phase 3

Clinical Trials (1)

NCT04433572Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

Phase 3

Dexamethasone Sodium Phosphate Injection, USP

Peripheral Arterial Diseases

Phase 4

Clinical Trials (1)

NCT01983449Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease